Stocktoria
Dr. Reddy's Laboratories Limited DRREDDY.NS
Dr. Reddy's Laboratories Limited (DRREDDY.NS) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 0.60% (safety: safe). FY2026 revenue was ₹335.9B at a 12.8% net margin.
Price from month-end closes (Yahoo) — for reference, not real-time.
How it ranks in Healthcare · percentile among 46 companies
Percentile vs other Healthcare companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.232 |
| Retained earnings / assets | 0.608 |
| EBIT / assets | 0.087 |
| Equity / liabilities | 1.896 |
FAQ
Is DRREDDY.NS financially healthy?
Dr. Reddy's Laboratories Limited's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does DRREDDY.NS pay a dividend, and is it safe?
Yes. Dr. Reddy's Laboratories Limited pays a dividend yielding about 0.60% with a 15.5% payout ratio, rated “safe” for safety.
How profitable is DRREDDY.NS?
In FY2026, Dr. Reddy's Laboratories Limited had a net margin of 12.8% and a return on equity of 11.4%.
Source: company filings via Yahoo Finance · IN · as of 2026-03-31. Figures in INR; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.